Medexus Reports Annual Meeting Results
September 19 2019 - 8:30AM
Medexus Pharmaceuticals Inc. (the
“
Company” or “
Medexus”) (TSXV:
MDP, OTCQB: PDDPF) announces voting results from its Annual Meeting
of Shareholders held on September 18, 2019 in Toronto, Ontario (the
“
Meeting”).
A total of 5,228,034 Common Shares, or 35.90% of
the total Common Shares issued and outstanding, were voted in
person or by proxy at the Meeting. Each director nominee was
elected by a show of hands. Based on proxies voted in connection
with the Meeting, voting by individual director was as follows:
Nominees |
Votes For |
% For |
Votes Withheld |
% Withheld |
Peter van der Velden |
5,147,573 |
99.91% |
4,533 |
0.09% |
Ken d’Entremont |
5,147,573 |
99.91% |
4,533 |
0.09% |
Sylvain Chrétien |
5,148,240 |
99.92% |
3,866 |
0.08% |
Michael Mueller |
5,146,351 |
99.89% |
5,755 |
0.11% |
Benoit Gravel |
5,146,351 |
99.89% |
5,755 |
0.11% |
Stephen Nelson |
5,146,573 |
99.89% |
5,533 |
0.11% |
Adele Gulfo |
5,146,573 |
99.89% |
5,533 |
0.11% |
Each of the other matters put forward before
shareholders for consideration and approval at the Meeting, as
described in the management information circular delivered in
connection with the Meeting, was duly approved by the requisite
number of votes.
About Medexus Pharmaceuticals
Inc.
Medexus is a leading specialty pharmaceutical
company with a strong North American commercial platform. The
Company’s vision is to provide the best healthcare products to
healthcare professionals and patients, through our core values of
Quality, Innovation, Customer Service and Teamwork. Medexus is
focused on the therapeutic areas of auto-immune disease and
pediatrics. The leading products are Rasuvo™ and Metoject®, a
unique formulation of methotrexate (auto-pen and pre-filled
syringe) designed to treat rheumatoid arthritis and other
auto-immune diseases; and Rupall™, an innovative allergy medication
with a unique mode of action.
For further information, please
contact:
Ken d’Entremont, Chief Executive Officer Medexus Pharmaceuticals
Inc. Tel: 905-676-0003E-mail: ken.dentremont@medexus.com
Roland Boivin, Chief Financial Officer Medexus Pharmaceuticals
Inc. Tel: 514-762-2626 ext. 202E-mail: roland.boivin@medexus.com
Investor Relations
(U.S.):Crescendo Communications, LLCTel:
+1-212-671-1020E-mail: mdp@crescendo-ir.com Investor
Relations (Canada):Frank CandidoDirect Financial
Strategies and Communication Inc.Tel: 514-969-5530E-mail:
frank.candido@medexus.com
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jul 2023 to Jul 2024